ARTEMIS DIANE T790M (An amino acid substitution at position 790 in EGFR, from a Threonine (T) to a Methionine (M)) mutation at hospital laboratories in comparison with central laboratory
Study identifier:D5160C00041
ClinicalTrials.gov identifier:NCT02991274
EudraCT identifier:N/A
CTIS identifier:N/A
Study Complete
Official Title
A study of T790M mutation testing in patient tissue and blood with various detection platforms at hospital laboratories in comparison with central testing
Medical condition
locally advanced or metastatic EGFR(+) NSCLC patients
Phase
Phase 4
Healthy volunteers
No
Study drug
-
Sex
All
Actual Enrollment
897
Study type
Observational
Age
18 Years +
Date
Study Start Date: 16 Jan 2017
Primary Completion Date: 29 Jun 2018
Study Completion Date: 29 Jun 2018
Study design
Allocation: N/A
Endpoint Classification: N/A
Intervention Model: Single Group Assignment
Masking: -
Primary Purpose: Diagnostic
Verification:
Verified 01 Jun 2019 by AstraZeneca
Sponsors
AstraZeneca
Collaborators
-
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|---|
| Other: T790M mutation test genomic testing of T790M mutation | Procedure/Surgery: genomic testing of T790M mutation patients will need to have genomic testing of T790M mutation at hospital laboratories and in central laboratory. |
Contacts
Investigators
Principal Investigator
Caicun Zhou
Shanghai Pulmonary Hospital
